85 related articles for article (PubMed ID: 20160659)
1. Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients.
Palladino C; Briz V; Policarpo SN; Silveira LF; de José MI; González-Tomé MI; Moreno D; León Leal JA; Mellado MJ; de Ory SJ; Ramos JT; Muñoz-Fernández MA
Pediatr Infect Dis J; 2010 Jun; 29(6):563-6. PubMed ID: 20160659
[TBL] [Abstract][Full Text] [Related]
2. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.
Blick G; Greiger-Zanlungo P; Gretz S; Han J; Dupree D; Garton T; Yau LH; Wine BC; Pakes GE;
Int J STD AIDS; 2012 Mar; 23(3):e18-22. PubMed ID: 22581890
[TBL] [Abstract][Full Text] [Related]
4. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
5. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
Pérez-Elias MJ; Sánchez-Conde M; Soriano V; Mallolas J; Luque I; Rodríguez-Alcántara F;
Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):28-32. PubMed ID: 19218000
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
7. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
8. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
Calza L; Manfredi R; Pocaterra D; Chiodo F
Int J STD AIDS; 2008 Aug; 19(8):541-4. PubMed ID: 18663041
[TBL] [Abstract][Full Text] [Related]
10. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
[TBL] [Abstract][Full Text] [Related]
11. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
[No Abstract] [Full Text] [Related]
12. Safety and efficacy of fosamprenavir in human immunodeficiency virus-infected pregnant women.
Martorell C; Theroux E; Bermudez A; Garb J; Kronschnabel D; Oie K
Pediatr Infect Dis J; 2010 Oct; 29(10):985. PubMed ID: 20859183
[No Abstract] [Full Text] [Related]
13. Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study).
Saumoy M; Tiraboschi J; Gutierrez M; Niubó J; Domingo P; Vila A; Podzamczer D
HIV Med; 2011 Aug; 12(7):438-41. PubMed ID: 21729229
[TBL] [Abstract][Full Text] [Related]
14. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
15. Fosamprenavir calcium plus ritonavir for HIV infection.
Torres HA; Arduino RC
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
[TBL] [Abstract][Full Text] [Related]
16. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P
HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients.
Wood R; Gathe JC; Givens N; Sedani S; Cheng K; Sievers J
HIV Clin Trials; 2013; 14(5):183-91. PubMed ID: 24144895
[TBL] [Abstract][Full Text] [Related]
19. Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients.
Perrella A; Sbreglia C; D'Antonio A; Atripaldi L; Perrella O
Clin Microbiol Infect; 2010 Jun; 16(6):676-8. PubMed ID: 19681945
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
